Aditxt, Inc. - ADTX STOCK NEWS

Aditxt, Inc. (Nasdaq: ADTX), a biotech innovation company, announced that CEO & Co-Founder Amro Albanna will present at the 2022 Virtual Growth Conference, hosted by Maxim Group LLC and M-Vest from March 28th - 30th between 9:00 a.m. - 5:00 p.m. EDT. This conference will cover various sectors, including biotech and healthcare, featuring presentations, discussions, and Q&As with executives. Aditxt focuses on mapping and reprogramming the immune system, aiming to address organ rejection and autoimmune diseases.

Aditxt has officially submitted two Emergency Use Authorization (EUA) applications for its AditxtScore™ COVID-19 test to the FDA, meeting the January 14 deadline. This comprehensive blood test assesses the immune response to COVID-19 and its variants, including Omicron. Notably, the test evaluates levels of neutralizing antibodies to the virus and those targeting its spike and nucleocapsid proteins. AditxtScore™ continues to be available during the FDA review process, aiming to provide critical insights into COVID-19 immunity.

Aditxt, Inc. (NASDAQ: ADTX) is participating in Edison Group’s Global Healthcare Open House Event from January 25 to 27, 2022. The virtual event, hosted in collaboration with the London Stock Exchange and Taylor Wessing, will cover topics including pharmaceuticals, AI, and healthcare technology. Presentations will be available for streaming on Edison’s website. Interested participants can register for free. Additionally, Aditxt focuses on immune system health and offers technology for immune monitoring and reprogramming, including the AditxtScore™ for COVID-19.

Aditxt, Inc. (ADTX), a biotech focused on immune system health, announced an online townhall on January 18, 2022, from 2:00 to 3:00 PM ET. Led by CEO Amro Albanna, the meeting will cover business updates, revenue strategy, and acquisition plans, followed by a Q&A session. Investors can submit questions in advance via email. Aditxt develops technologies for immune monitoring and reprogramming aimed at improving health and addressing various immune-related issues.

Aditxt, Inc. (NASDAQ: ADTX) announced an amendment to its Exclusive License Agreement with Stanford University, extending its license for AditxtScore™ technology. This amendment grants Aditxt worldwide exclusivity in utilizing the technology for various applications, including organ transplantation and disease detection. The technology aims to enhance treatment personalization and clinical monitoring. Notably, Aditxt has also established an Immune Monitoring Center in Richmond, VA, and secured necessary accreditations to advance its operations.

Aditxt (NASDAQ: ADTX) has signed a share exchange agreement to acquire AiPharma Global Holdings, enhancing its position in the infectious disease therapeutics market. The transaction consists of two phases: an initial acquisition of 9.5% of AiPharma for 4.8 million shares and $250,000, followed by a secondary closing for the remaining 90.5% for approximately 39.9 million shares and another $250,000. AiPharma holds exclusive rights to the antiviral drug Avigan, with regulatory approvals in several countries, but its recent Phase 3 trial did not achieve statistical significance.

Aditxt, a biotech company, has announced a non-binding letter of intent to acquire a firm specializing in Point-of-Care diagnostics. This acquisition aims to enhance AditxtScore’s portfolio with at-home COVID-19 rapid antigen test kits and other diagnostics. Key benefits include access to global manufacturing capabilities, a seasoned management team, and various growth opportunities in early disease detection. However, the acquisition's completion hinges on satisfactory due diligence and negotiations, with an exclusivity period until January 31, 2022. Aditxt has also provided a secured loan to the target company.

Aditxt, Inc. (Nasdaq: ADTX) has successfully closed its underwritten public offering of 16,575,000 units, comprising shares of common stock and warrants. The offering price was set at $1.05 per unit, yielding gross proceeds of $17,403,750 before deductions. Each warrant allows the purchase of one share at $1.15, expiring five years post-issuance. An over-allotment option permits the underwriter to buy an additional 2,486,250 shares or warrants. Dawson James Securities, Inc. managed the offering, with legal counsel provided by Sheppard Mullin and Schiff Hardin.

Aditxt, Inc. (NASDAQ: ADTX) has amended its agreement with AiPharma Global, extending the deadline for a definitive agreement from November 30, 2021, to December 16, 2021. The amendment also eliminates a $4 million termination fee and reduces AiPharma's borrowing capacity from $8.5 million to $8 million. A cash payment of $500,000 will be required at closing. CEO Amro Albanna expressed optimism about aligning opportunities with AiPharma for 2022, but noted that the agreement remains subject to due diligence and various approvals.